PROCEPT BioRobotics Aktie News

Chicago Capital added 999,873 shares of Procept BioRobotics with an estimated purchase value of $45.65 million based on the average price for the quarter. The transaction represents a trade size equal to 1.12% of Chicago Capital's 13F reportable assets under management (AUM) for the period.

SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The Company's management will host a co...

PROCEPT BioRobotics stands out in BPH therapy with its unique Aquablation technology and razor-and-blade business model, driving strong, recurring growth. PRCT's robust R&D investment, expanding indications, and international momentum support margin expansion, scalability, and long-term growth in its niche market. Valuation is attractive at current levels, with a DCF-derived target price of $50...

It is tempting to believe the next Nvidia (NASDAQ:NVDA ) or Palantir (NASDAQ:PLTR ) is hiding in plain sight and will quickly give you multibagger returns.

Procept BioRobotics Corporation is in the early stages of penetrating a massive $20B BPH surgery market with its innovative, recurring-revenue robotic systems. The company's strong revenue and install base growth, favorable reimbursement, and increasing ASPs support my buy rating and $44 fair value estimate. Gross margin expansion is expected from pricing power, scale, and cost control, with br...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Kevin Waters - Executive VP & CFO Larry L. Wood - Independent Director Matthew James Bacso - Vice President of Investor Relations Reza Zadno - President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C.

Procept BioRobotics (PRCT -5.28%), a medical technology company specializing in robotic surgical systems for benign prostatic hyperplasia (BPH) treatment, posted second-quarter 2025 results on August 6, 2025. The company reported GAAP revenue of $79.2 million, surpassing analyst estimates.

Image source: The Motley Fool.